Literature DB >> 31897496

Uterine Corpus Malignancies in Appalachia Kentucky: Incidence, Survival, and Related Health Disparities.

Marian Symmes Johnson1, Thomas C Tucker1, Quan Chen1, Bin Huang1, Christopher P DeSimone1, Rachel W Miller1, Lauren A Baldwin1, Tricia I Fredericks1, Brian T Burgess1, Frederick R Ueland1.   

Abstract

OBJECTIVES: Uterine cancer is the nation's most common gynecologic malignancy, but it is understudied in the geographically and socioeconomically diverse state of Kentucky (KY). Our aim was to assess the frequency, distribution, and survival of uterine corpus malignancies in KY, and specifically the differences between Appalachia (AP) and non-Appalachia (NAP) KY.
METHODS: This population-based cohort study used Surveillance, Epidemiology, and End Results data and the Kentucky Cancer Registry to study uterine corpus malignancy between January 1, 2000 and December 31, 2014. The analysis looked at the incidence between diagnoses in AP and NAP. The evaluation criteria included tumor histology (type I, type II, sarcoma, and mixed uterine malignancy), age, race, smoking status, stage at diagnosis, insurance status, and county of residence at diagnosis.
RESULTS: The overall age-adjusted incidence rate and survival are similar for US and KY populations; however, histologic types and distribution differ. Compared with the United States, the incidence of corpus cancers in KY is higher for type I (P = 0.03), but lower for type II (P = 0.003), sarcoma (P = 0.006), and mixed (P < 0.001). AP KY has a higher incidence of type I (P < 0.0001) and mixed malignancy (P = 0.04), younger age at diagnosis (P < 0.0001), larger non-Hispanic white population (P < 0.0001), fewer smokers (P = 0.002), and more uninsured and Medicaid recipients (P < 0.0001) compared with NAP KY. The hazard ratio for death is similar in AP and NAP KY (0.896; 95% confidence interval 0.795-1.009).
CONCLUSIONS: Type I and mixed uterine corpus cancers have a higher age-adjusted incidence and a younger age at diagnosis in AP compared with NAP KY.

Entities:  

Mesh:

Year:  2020        PMID: 31897496      PMCID: PMC8120481          DOI: 10.14423/SMJ.0000000000001057

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  30 in total

Review 1.  Association of tamoxifen and uterine sarcoma.

Authors:  D Lawrence Wickerham; Bernard Fisher; Norman Wolmark; John Bryant; Joseph Costantino; Leslie Bernstein; Carolyn D Runowicz
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity.

Authors:  H Fujii; M Yoshida; Z X Gong; T Matsumoto; Y Hamano; M Fukunaga; R H Hruban; E Gabrielson; T Shirai
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

Review 4.  Uterine carcinosarcoma: A review of the literature.

Authors:  Leigh A Cantrell; Stephanie V Blank; Linda R Duska
Journal:  Gynecol Oncol       Date:  2015-03-21       Impact factor: 5.482

5.  Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status.

Authors:  Gary V Walker; Stephen R Grant; B Ashleigh Guadagnolo; Karen E Hoffman; Benjamin D Smith; Matthew Koshy; Pamela K Allen; Usama Mahmood
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

Review 6.  Uterine sarcomas: a review.

Authors:  Emanuela D'Angelo; Jaime Prat
Journal:  Gynecol Oncol       Date:  2009-10-23       Impact factor: 5.482

7.  Obesity and age at diagnosis of endometrial cancer.

Authors:  Nicole S Nevadunsky; Anne Van Arsdale; Howard D Strickler; Alyson Moadel; Gurpreet Kaur; Joshua Levitt; Eugenia Girda; Mendel Goldfinger; Gary L Goldberg; Mark H Einstein
Journal:  Obstet Gynecol       Date:  2014-08       Impact factor: 7.661

8.  Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study.

Authors:  Hannah P Yang; Nicolas Wentzensen; Britton Trabert; Gretchen L Gierach; Ashley S Felix; Marc J Gunter; Albert Hollenbeck; Yikyung Park; Mark E Sherman; Louise A Brinton
Journal:  Am J Epidemiol       Date:  2012-11-21       Impact factor: 4.897

9.  Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.

Authors:  Sandra E Brooks; Min Zhan; Timothy Cote; Claudia R Baquet
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

10.  Trends of uterine carcinosarcoma in the United States.

Authors:  Koji Matsuo; Malcolm S Ross; Hiroko Machida; Erin A Blake; Lynda D Roman
Journal:  J Gynecol Oncol       Date:  2018-01-05       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.